When CYP enzymes are inhibited by berberine, what happens to the concentration of co-administered medications?

The companion medication stays in the bloodstream longer at higher concentrations

The inhibition of Cytochrome P450 enzymes by berberine directly compromises the body's ability to eliminate other drugs that are substrates for those specific enzymes. Since these CYP enzymes are responsible for the breakdown and clearance of many medications, their inhibition means the drug remains circulating in the systemic circulation for an extended period. This prolonged presence results in higher average drug concentrations than intended by the prescriber. This pharmacokinetic change significantly increases the potential for the patient to experience the full spectrum of the drug's side effects, potentially reaching toxic levels if the dose is not adjusted to account for the impaired metabolism.